**Supplementary table 6: Adverse reaction recorded, at initial treatment and 3-month follow-up.**

|  |  |  |
| --- | --- | --- |
| This table shows the percentage of all paediatric patients for whom an adverse reaction was recorded by type of reaction between 1 March 2015 and 29 February 2016. **Adverse reactions, % (n)**  | **Initial treatment** **(n=278)**  | **3-month follow-up** **(n=121)**  |
| Adverse reaction recorded Yes=  | 1% (4)  | 5% (6)  |
| Abdominal pain  | 0% (0)  | 0% (0)  |
| Alopecia  | 0% (0)  | 0% (0)  |
| Angioedema of upper airway  | 0% (0)  | 0% (0)  |
| Arthralgia  | 0% (0)  | 0% (0)  |
| Blood abnormality  | 0% (0)  | 0.8% (1)  |
| Bronchospasm (cough/wheeze/dyspnoea)  | 0% (0)  | 0% (0)  |
| Cardiac failure  | 0% (0)  | 0% (0)  |
| Chest pain  | 0% (0)  | 0% (0)  |
| Chills  | 0% (0)  | 0% (0)  |
| Confirmed demyelination  | 0% (0)  | 0% (0)  |
| Death  | 0% (0)  | 0% (0)  |
| Difficulty breathing  | 0% (0)  | 0.8% (1)  |
| Dizziness  | 0% (0)  | 0% (0)  |
| Fatigue  | 0% (0)  | 0% (0)  |
| Fever  | 0% (0)  | 2% (2)  |
| Flushing  | 0% (0)  | 0% (0)  |
| Headache  | 0% (0)  | 0% (0)  |
| Hypotension  | 0% (0)  | 0% (0)  |
| Infection  | 0% (0)  | 0% (0)  |
| Injection site reaction  | 0% (0)  | 0% (0)  |
| Itching  | 0% (0)  | 0% (0)  |
| Limb weakness  | 0% (0)  | 0% (0)  |
| Malignancy  | 0% (0)  | 0% (0)  |
| Nausea  | 0% (0)  | 0% (0)  |
| Panic attacks  | 0% (0)  | 0% (0)  |
| Rash  | 0% (0)  | 2% (2)  |
| Serum sickness-like reaction  | 0% (0)  | 0% (0)  |
| Urticaria  | 0% (0)  | 0% (0)  |
| Other  | 1% (4)  | 2% (2)  |